Literatur zu Kapitel 8.9: Akute Promyelozytenleukämie (APL; M3-Leukämie)

 Druckversion

Autor/en: H. Link
Letzte Änderung: 01.07.2008

• Ades L et al.
  Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results.
  ASH Annual Meeting Abstracts 2005;106:544.
  http://abstracts.hematologylibrary.org/cgi/content/ abstract/ashmtg;106/11/544 (08.02.08).




• Ades L et al.
  Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
  J Clin Oncol 2006;24:5703-5710.




• Asou N et al.
  A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study.
  Blood 2007;110:59-66.
  http://bloodjournal.hematologylibrary.org/cgi/content/ abstract/bloodjournal;110/1/59 (08.02.08).




• Beaumont M et al.
  Therapy-related acute promyelocytic leukemia.
  J Clin Oncol 2003;21:2123-2137.




• Breitman TR, Collins SJ, Keene BR.
  Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid.
  Blood 1981;57:1000-1004.




• Cephalon.
  Trisenox, Fachinformation.
  Rote Liste Service GmbH FachInfo-Service, Berlin, 2006.




• Cheson BD et al.
  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
  J Clin Oncol 2003;21:4642-4649.




• De Botton S et al.
  Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
  J Clin Oncol 2005;23:120-126.




• De Botton S et al.
  Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
  Leukemia 2006;20:35-41.




• Douer D et al.
  High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia.
  Blood 1996;87:308-313.




• Douer D, Tallman MS.
  Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
  J Clin Oncol 2005;23:2396-2410.




• Douer D.
  ATO: the forefront of APL treatment?
  Blood 2006;107:2588-2589.
  http://bloodjournal.hematologylibrary.org




• Esteve J et al.
  Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
  Leukemia 2007;21:446-452.
  http://dx.doi.org/10.1038/sj.leu.2404501 (08.02.08).




• Estey E et al.
  Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
  Blood 2006;107:3469-3473.




• Fenaux P et al.
  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial.
  Blood 1993;82:3241-3249.




• Fenaux P et al.
  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
  Blood 1999;94:1192-1200.
  http://www.bloodjournal.org/cgi/content/full/94/4/1192
  http://www.bloodjournal.org/cgi/content/abstract/94/4/1192 (08.02.08)




• Fenaux P et al.
  Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.
  Leukemia 2000;14:1371-1377.




• Gabert J et al.
  Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
  Leukemia 2003;17:2318-2357.




• Gallagher RE et al.
  Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
  Leukemia 2006;20:556-562.




• Grimwade D et al.
  Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies".
  Blood 2000;96:1297-1308.




• Hillestad LK.
  Acute promyelocytic leukemia.
  Acta Med Scand 1957;159:189-194.




• Huang ME et al.
  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.
  Blood 1988;72:567-572.




• Jurcic JG et al.
  Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.
  Blood 2001;98:2651-2656.
  http://bloodjournal.hematologylibrary.org/cgi/content/ abstract/bloodjournal;98/9/2651 (08.02.08).




• Liesveld JL et al.
  Acute Myelogenous Leukemia.
  Williams Hematology, 7th edn. New York, McGraw-Hill Medical, 2006.




• Lo-Coco F, Ammatuna E.
  The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment.
  Hematology 2006;2006:156-161.




• Lo-Coco F et al.
  Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.
  ASH Annual Meeting Abstracts 2004a;104:392.
  http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;104/11/392 (08.02.08).




• Lo-Coco F et al.
  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.
  Blood 2004b;104:1995-1999.
  http://asheducationbook.hematologylibrary.org/cgi/content/ abstract/bloodbook;2006/1/156 (08.02.08).




• Lu J, Chew EH, Holmgren A.
  Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
  Proc Nat Acad Sci 2007;104:12288-12293.
  http://www.pnas.org/cgi/content/abstract/104/30/12288 (08.02.08).




• Mandelli F et al.
  Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
  Blood 1997;90:1014-1021.




• Mathews V et al.
  Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.
  Blood 2006;107:2627-2632.
  http://bloodjournal.hematologylibrary.org/cgi/content/ abstract/bloodjournal;107/7/2627 (08.02.08).




• Muindi J et al.
  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.
  Blood 1992;79:299-303.




• Otero JC, Santillana S, Fereyros G.
  High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia.
  Blood 1996;88:377.




• Powell BL.
  Effect of consolidation with arsenic trioxide (As₂O₃) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710.
  ASCO Meeting Abstracts 2007;25:2.
  http://meeting.jco.org/cgi/content/abstract/25/18_suppl/2 (08.02.08).




• Pulsoni A et al.
  Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.
  Blood 2002;100:1972-1976.




• Roboz GJ et al.
  Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
  Blood 2000;96:1525-1530.




• Roche Pharma AG.
  Vesanoid 10 mg Weichkapseln.
  Rote Liste Service GmbH, Berlin; 2006.
  http://www.fachinfo.de/FachInfo/data/fi/pdf/00/79/007969.pdf (08.02.08).




• Sainty D et al.
  A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED 1 European Coomunity-Concerted Acion "Molecular Cytogenetic Diagnosis in Haematological Malignancies".
  Blood 2000;96:1287-1296.




• Sancho JM et al.
  Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
  Int J Hematol 2007;86:33-36.




• Sanz MA.
  Treatment of acute promyelocytic leukemia. Hematology.
  American Society of Hematology Educational Program 2006, 147-155.




• Sanz MA, Fenaux P, Lo CF.
  Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
  Haematologica 2005a;90:1231-1235.




• Sanz MA, Tallman MS, Lo-Coco F.
  Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia.
  Blood 2005b;105:3019-3025.




• Sanz MA et al.
  A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
  Blood 1999;94:3015-3021.




• Sanz MA et al.
  Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
  Blood 2000;96:1247-1253.




• Sanz MA et al.
  Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
  Blood 2004a;103:1237-1243.




• Sanz MA et al.
  All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia.
  Blood 2004b;104:3490-3493.




• Sanz MA et al.
  Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.
  Bone Marrow Transplant 2007;39:461-469.
  http://dx.doi.org/10.1038/sj.bmt.1705620 (08.02.08).




• Schnittger S et al.
  New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.
  Blood 2003;102:2746-2755.




• Shen ZX et al.
  Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
  Blood 1997;89:3354-3360.




• Shen ZX et al.
  All-trans retinoic acid/As₂O₃ combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
  Proc Natl Acad Sci USA 2004;101:5328-5335.




• Soignet SL et al.
  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
  J Clin Oncol 2001;19:3852-3860.




• Tallman MS et al.
  All-trans-retinoic acid in acute promyelocytic leukemia.
  N Engl J Med 1997;337:1021-1028.




• Tallman MS et al.
  Acute promyelocytic leukemia: evolving therapeutic strategies.
  Blood 2002;99:759-767.




• Tallman M, Abutalib S, Altman J.
  The Double Hazard of Thrombophilia and Bleeding in Acute Promyelocytic Leukemia.
  Semin Thromb Hemost 2007;33(4):330-338.




• Warrell RP Jr et al.
  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).
  N Engl J Med 1991;324:1385-1393.




• Wiley JS, Firkin FC.
  Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group.
  Leukemia 1995;9:774-778.




• Zhou GB et al.
  Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia.
  PLoS Medicine 2005;2:e12.
  http://dx.doi.org/10.1371%2Fjournal.pmed.0020012 (08.02.08).




• Zhou DC et al.
  Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
  Blood 2002;99:1356-1363.

Herausgeber: Prof. Dr. H. Link
Herausgeberbeirat: Prof. Dr. P. Albers, Prof. Dr. R. Andreesen, Priv.-Doz. Dr. A. Böhme, Prof. Dr. C. Bokemeyer, Prof. Dr. U. Creutzig, Prof. Dr. G. Ehninger, Prof. Dr. M. Freund, Prof. Dr. C. Garbe, Dr. N. Gökbuget, Prof. Dr. M. Hallek, Prof. Dr. J.T. Hartmann, Prof. Dr. R. Hehlmann, Prof. emerit. Dr. H. Heimpel, Prof. Dr. A. Hochhaus, Prof. Dr. K. Höffken, Dr. G. Hübner, Prof. Dr. Th. Junginger, Priv.-Doz. Dr. U. Kaiser, Priv.-Doz. Dr. R. Kath, Prof. Dr. C.-H. Köhne, Dr. R. Mahlberg, Prof. Dr. A. Matzdorff, Prof. Dr. R.-P. Müller, Prof. Dr. J. Preiß, Prof. Dr. H.-J. Schmoll, Prof. Dr. G. von Minckwitz